Serum bone biomarkers and oral/systemic bone loss in humans

Jeffrey B Payne, J. A. Stoner, H. M. Lee, P. V. Nummikoski, Richard A Reinhardt, L. M. Golub

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We recently reported that subantimicrobial-dose doxycycline (SDD) significantly reduced serum bone-resorption biomarkers in subgroups of post-menopausal women. We hypothesize that changes in serum bone biomarkers are associated not only with systemic bone mineral density (BMD) changes, but also with alveolar bone changes over time. One hundred twenty-eight eligible post-menopausal women with periodontitis and systemic osteopenia were randomly assigned to receive SDD or placebo tablets twice daily for two years, adjunctive to periodontal maintenance. Sera were analyzed for bone biomarkers. As expected, two-year changes in a serum bone biomarker were significantly associated with systemic BMD loss at the lumbar spine (osteocalcin, bone-turnover biomarker, p = 0.0002) and femoral neck (osteocalcin p = 0.0025). Two-year changes in serum osteocalcin and serum pyridinoline-crosslink fragment of type I collagen (ICTP; bone-resorption biomarker) were also significantly associated with alveolar bone density loss (p < 0.0001) and alveolar bone height loss (p = 0.0008), respectively. Thus, we have shown that serum bone biomarkers are associated with not only systemic BMD loss, but with alveolar bone loss as well. Clinical Trial Registration Information: Protocol registered at ClinicalTrials.gov, NCT00066027.Abbreviations: bone mineral density (BMD), bone-specific alkaline phosphatase (BSAP), computer-assisted densitometric image analysis (CADIA), confidence interval (CI), deoxypyridinoline-containing degradation fragment of the C-terminal telopeptide region of type I collagen (CTX), coefficient of variation (CV), dual-energy x-ray absorptiometry (DXA), pyridinoline-crosslink-containing degradation fragment of the C-terminal telopeptide region of type I collagen (ICTP), and subantimicrobial-dose doxycycline (SDD).

Original languageEnglish (US)
Pages (from-to)747-751
Number of pages5
JournalJournal of Dental Research
Volume90
Issue number6
DOIs
StatePublished - Jun 1 2011

Fingerprint

Biomarkers
Bone Density
Bone and Bones
Alveolar Bone Loss
Serum
Doxycycline
Osteocalcin
Bone Resorption
Computer-Assisted Image Processing
Bone Remodeling
Metabolic Bone Diseases
Periodontitis
Femur Neck
Collagen Type I
Tablets
Alkaline Phosphatase
Spine
Placebos
Maintenance
X-Rays

Keywords

  • bone
  • osteopenia
  • periodontitis
  • post-menopausal
  • serum biomarkers
  • subantimicrobial-dose doxycycline

ASJC Scopus subject areas

  • Dentistry(all)

Cite this

Serum bone biomarkers and oral/systemic bone loss in humans. / Payne, Jeffrey B; Stoner, J. A.; Lee, H. M.; Nummikoski, P. V.; Reinhardt, Richard A; Golub, L. M.

In: Journal of Dental Research, Vol. 90, No. 6, 01.06.2011, p. 747-751.

Research output: Contribution to journalArticle

Payne, Jeffrey B ; Stoner, J. A. ; Lee, H. M. ; Nummikoski, P. V. ; Reinhardt, Richard A ; Golub, L. M. / Serum bone biomarkers and oral/systemic bone loss in humans. In: Journal of Dental Research. 2011 ; Vol. 90, No. 6. pp. 747-751.
@article{bbe5cc996852444e96c56da4397db078,
title = "Serum bone biomarkers and oral/systemic bone loss in humans",
abstract = "We recently reported that subantimicrobial-dose doxycycline (SDD) significantly reduced serum bone-resorption biomarkers in subgroups of post-menopausal women. We hypothesize that changes in serum bone biomarkers are associated not only with systemic bone mineral density (BMD) changes, but also with alveolar bone changes over time. One hundred twenty-eight eligible post-menopausal women with periodontitis and systemic osteopenia were randomly assigned to receive SDD or placebo tablets twice daily for two years, adjunctive to periodontal maintenance. Sera were analyzed for bone biomarkers. As expected, two-year changes in a serum bone biomarker were significantly associated with systemic BMD loss at the lumbar spine (osteocalcin, bone-turnover biomarker, p = 0.0002) and femoral neck (osteocalcin p = 0.0025). Two-year changes in serum osteocalcin and serum pyridinoline-crosslink fragment of type I collagen (ICTP; bone-resorption biomarker) were also significantly associated with alveolar bone density loss (p < 0.0001) and alveolar bone height loss (p = 0.0008), respectively. Thus, we have shown that serum bone biomarkers are associated with not only systemic BMD loss, but with alveolar bone loss as well. Clinical Trial Registration Information: Protocol registered at ClinicalTrials.gov, NCT00066027.Abbreviations: bone mineral density (BMD), bone-specific alkaline phosphatase (BSAP), computer-assisted densitometric image analysis (CADIA), confidence interval (CI), deoxypyridinoline-containing degradation fragment of the C-terminal telopeptide region of type I collagen (CTX), coefficient of variation (CV), dual-energy x-ray absorptiometry (DXA), pyridinoline-crosslink-containing degradation fragment of the C-terminal telopeptide region of type I collagen (ICTP), and subantimicrobial-dose doxycycline (SDD).",
keywords = "bone, osteopenia, periodontitis, post-menopausal, serum biomarkers, subantimicrobial-dose doxycycline",
author = "Payne, {Jeffrey B} and Stoner, {J. A.} and Lee, {H. M.} and Nummikoski, {P. V.} and Reinhardt, {Richard A} and Golub, {L. M.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1177/0022034511402993",
language = "English (US)",
volume = "90",
pages = "747--751",
journal = "Journal of Dental Research",
issn = "0022-0345",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Serum bone biomarkers and oral/systemic bone loss in humans

AU - Payne, Jeffrey B

AU - Stoner, J. A.

AU - Lee, H. M.

AU - Nummikoski, P. V.

AU - Reinhardt, Richard A

AU - Golub, L. M.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - We recently reported that subantimicrobial-dose doxycycline (SDD) significantly reduced serum bone-resorption biomarkers in subgroups of post-menopausal women. We hypothesize that changes in serum bone biomarkers are associated not only with systemic bone mineral density (BMD) changes, but also with alveolar bone changes over time. One hundred twenty-eight eligible post-menopausal women with periodontitis and systemic osteopenia were randomly assigned to receive SDD or placebo tablets twice daily for two years, adjunctive to periodontal maintenance. Sera were analyzed for bone biomarkers. As expected, two-year changes in a serum bone biomarker were significantly associated with systemic BMD loss at the lumbar spine (osteocalcin, bone-turnover biomarker, p = 0.0002) and femoral neck (osteocalcin p = 0.0025). Two-year changes in serum osteocalcin and serum pyridinoline-crosslink fragment of type I collagen (ICTP; bone-resorption biomarker) were also significantly associated with alveolar bone density loss (p < 0.0001) and alveolar bone height loss (p = 0.0008), respectively. Thus, we have shown that serum bone biomarkers are associated with not only systemic BMD loss, but with alveolar bone loss as well. Clinical Trial Registration Information: Protocol registered at ClinicalTrials.gov, NCT00066027.Abbreviations: bone mineral density (BMD), bone-specific alkaline phosphatase (BSAP), computer-assisted densitometric image analysis (CADIA), confidence interval (CI), deoxypyridinoline-containing degradation fragment of the C-terminal telopeptide region of type I collagen (CTX), coefficient of variation (CV), dual-energy x-ray absorptiometry (DXA), pyridinoline-crosslink-containing degradation fragment of the C-terminal telopeptide region of type I collagen (ICTP), and subantimicrobial-dose doxycycline (SDD).

AB - We recently reported that subantimicrobial-dose doxycycline (SDD) significantly reduced serum bone-resorption biomarkers in subgroups of post-menopausal women. We hypothesize that changes in serum bone biomarkers are associated not only with systemic bone mineral density (BMD) changes, but also with alveolar bone changes over time. One hundred twenty-eight eligible post-menopausal women with periodontitis and systemic osteopenia were randomly assigned to receive SDD or placebo tablets twice daily for two years, adjunctive to periodontal maintenance. Sera were analyzed for bone biomarkers. As expected, two-year changes in a serum bone biomarker were significantly associated with systemic BMD loss at the lumbar spine (osteocalcin, bone-turnover biomarker, p = 0.0002) and femoral neck (osteocalcin p = 0.0025). Two-year changes in serum osteocalcin and serum pyridinoline-crosslink fragment of type I collagen (ICTP; bone-resorption biomarker) were also significantly associated with alveolar bone density loss (p < 0.0001) and alveolar bone height loss (p = 0.0008), respectively. Thus, we have shown that serum bone biomarkers are associated with not only systemic BMD loss, but with alveolar bone loss as well. Clinical Trial Registration Information: Protocol registered at ClinicalTrials.gov, NCT00066027.Abbreviations: bone mineral density (BMD), bone-specific alkaline phosphatase (BSAP), computer-assisted densitometric image analysis (CADIA), confidence interval (CI), deoxypyridinoline-containing degradation fragment of the C-terminal telopeptide region of type I collagen (CTX), coefficient of variation (CV), dual-energy x-ray absorptiometry (DXA), pyridinoline-crosslink-containing degradation fragment of the C-terminal telopeptide region of type I collagen (ICTP), and subantimicrobial-dose doxycycline (SDD).

KW - bone

KW - osteopenia

KW - periodontitis

KW - post-menopausal

KW - serum biomarkers

KW - subantimicrobial-dose doxycycline

UR - http://www.scopus.com/inward/record.url?scp=79956055025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956055025&partnerID=8YFLogxK

U2 - 10.1177/0022034511402993

DO - 10.1177/0022034511402993

M3 - Article

VL - 90

SP - 747

EP - 751

JO - Journal of Dental Research

JF - Journal of Dental Research

SN - 0022-0345

IS - 6

ER -